Press Releases

  • Nov. 24, 2011 biOasis Enters Research, Evaluation and Option Agreement with Shire Human Genetic Therapies, Inc.

    Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V:BTI) announced today that it has entered into a research, evaluation and option agreement with Shire Human Genetic Therapies, Inc. (Shire) to evaluate biOasis’s Transcend technology in the area of lysosomal storage disorders (LSDs). In connection with this agreement, biOasis and Shire are undertaking certain experiments at their own… Read more »

  • Nov. 1, 2011 biOasis Transcend Vector Delivers an Anti-Amyloid Beta (A?) Antibody To The Brain

    Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V:BTI) today announced test results from its Transcend therapeutic development program directed towards the delivery of targeted therapeutic compounds to the brain which showed that Transcend can deliver an anti-amyloid beta antibody to the brain. The work was conducted on behalf of the Company by the National Research Council… Read more »

  • Oct. 17, 2011 biOasis Receives Final Results from BC Cancer Research Centre Herceptin® Studies

    Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V:BTI) announced today the results from two additional studies conducted by the BC Cancer Research Centre (BCCRC). The additional studies confirmed and extended earlier data showing that BT2111, a conjugate made up of biOasis Transcend vector and trastuzumab (trade name Herceptin®), a humanized monoclonal antibody used clinically in the… Read more »

  • Sep. 2, 2011 Option Grant – biOasis Technologies Inc.

    Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V:BTI) announces that it has granted options to its officers, employees, consultants and members of the board of directors. A total of 2,275,000 options have been granted effective at the close of business on September 1st, 2011. The options are exercisable at a price of $0.52 per share until… Read more »

  • Aug. 18, 2011 2011-2012 Board of Directors and Officers

    Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V:BTI) announces its board of directors elected by the shareholders at its recently held Annual General Meeting held July 26, 2011: Robin Hutchison* Chairman of the Board David Clark CATerry Pearson Ph.D.Chris Fibiger PH.D.Michael Hutchison Q.C.Ron Erickson* Chairman of the Audit CommitteeMember of the Audit CommitteeMember of the Compensation,… Read more »

  • Aug. 10, 2011 biOasis announces completion of acquisition of Intellectual Property

    Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V:BTI) (the “Company”) announces that its wholly owned subsidiary biOasis Advanced Technologies Inc. (“BAT”) has completed the acquisition of certain Intellectual Property pursuant to a Worldwide Assignment dated June 16, 2011 on terms as previously disclosed. On August 5, 2011, the closing date, the Company paid $25,000 in cash… Read more »

  • Aug. 5, 2011 biOasis announces acquisition of Intellectual Property

    Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V:BTI) (the “Company”) announces that its wholly owned subsidiary biOasis Advanced Technologies Inc. has entered into a worldwide assignment (the “Assignment”) to acquire certain Intellectual Property. Pursuant to the Assignment, the Company will pay $25,000 in cash and will issue 350,000 warrants at an exercise price of $0.575 and… Read more »

  • Jul. 6, 2011 biOasis Announces Transcend Vector Results with a Therapeutic Antibody That Targets Metastatic Breast Cancer

    Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V:BTI) today announced results from two studies designed to assess the therapeutic potential of its Transcend vector in treating metastatic breast cancer. In these studies trastuzumab (tradename Herceptin®), a humanized monoclonal antibody used clinically in the treatment of HER2-positive (“HER2+”) breast cancer, was chemically linked to the Transcend delivery… Read more »

  • Jun. 24, 2011 biOasis Director Resigns

    Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V:BTI) announces that Mr. David Howard has resigned from the board of directors and audit committee. Mr. Howard has been a member of the board since August 9th, 2010. “We would like to thank David for his valuable contribution and service on the board of directors of the Company,”… Read more »

  • Jun. 23, 2011 biOasis to Present on Drug Delivery at International Conference on Cerebral Vascular Biology

    Vancouver, British Columbia–(Business Wire)– biOasis Technologies Inc. (TSX:V BTI) is pleased to announce that it will be presenting data on its Transcend technology for delivery of drugs into the brain at the 9th annual International Conference on Cerebral Vascular Biology being held in Leiden Netherlands from June 21-25th 2011. Dr. Reinhard Gabathuler, biOasis VP of… Read more »